Fredun Pharma

{
  "main_header": {
    "sid": 1002605,
    "name": "Fredun Pharma",
    "stock_name": "Fredun Pharma",
    "full_name": "Fredun Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/fredun-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,353.00",
    "chg": -53.8,
    "chgp": "-3.82%",
    "dir": -1,
    "prev_price": "1,406.80",
    "mcapval": "2,281.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 539730,
    "symbol": "FREDUN",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE194R01017",
    "curr_date": "Oct 01, 03:30 PM",
    "curr_time": "12:08 PM",
    "last_traded_at": "Oct 01, 03:30 PM IST",
    "bse_nse_vol": "11.12 k",
    "exc_status": "Active",
    "traded_date": "Oct 01, 2026",
    "traded_date_str": "2026 10 01",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/fredun-pharma-1002605-0&utm_source=Website_LockedLinks_StockPageName",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Fredun Pharmaceuticals Ltd is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/fredun-pharmaceuticals-ltd-is-rated-buy-4212295",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/FredunPharmaceu_mojoScore_4212295.png",
        "date": "2026-10-03 10:10:43",
        "description": "Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 21 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 October 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Fredun Pharmaceuticals Gains 4.22%: Valuation Shift and Strong Fundamentals Drive the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/fredun-pharmaceuticals-gains-422-valuation-shift-and-strong-fundamentals-drive-the-week-4205888",
        "imagepath": "",
        "date": "2026-09-26 14:00:35",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>21 Sep:</strong> Rating downgraded to Buy amid expensive valuation</p>\n                    <p><strong>22 Sep:</strong> Valuation shift signals changing price attractiveness</p>\n                    <p><strong>24 Sep:</strong> Stock price dips amid broader market weakness</p>\n                    <p><strong>25 Sep:</strong> Week closes with modest gain at Rs.1,360.90</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,305.85</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,360.90</div>..."
      },
      {
        "title": "Fredun Pharmaceuticals Downgraded to Buy Amid Expensive Valuation Despite Strong Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/fredun-pharmaceuticals-downgraded-to-buy-amid-expensive-valuation-despite-strong-financials-4200697",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/FredunPharmaceu_mojoScore_4200697.png",
        "date": "2026-09-22 08:53:15",
        "description": "Fredun Pharmaceuticals Ltd has seen its investment rating downgraded from Strong Buy to Buy as of 21 Sep 2026, primarily due to a shift in valuation metrics despite continued robust financial performance and positive technical indicators. The micro-cap pharmaceutical company’s Mojo Score now stands at 77.0, reflecting a recalibrated outlook that balances impressive growth with stretched market multiples."
      },
      {
        "title": "Fredun Pharmaceuticals Ltd: Valuation Shift Signals Changing Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/fredun-pharmaceuticals-ltd-valuation-shift-signals-changing-price-attractiveness-4200200",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/FredunPharmaceu_valuationdot_4200200.png",
        "date": "2026-09-22 08:01:13",
        "description": "Fredun Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Fredun Pharmaceuticals Declines 7.62% Amid Valuation Shift and Circuit Breaker Event",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/fredun-pharmaceuticals-declines-762-amid-valuation-shift-and-circuit-breaker-event-4198201",
        "imagepath": "",
        "date": "2026-09-19 13:02:25",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>15 Sep:</strong> Stock opens at Rs.1,325.05, down 6.26% amid broad market weakness</p>\n                    <p><strong>16 Sep:</strong> Fredun hits lower circuit at Rs.1,197.70, down 9.8%, amid panic selling</p>\n                    <p><strong>16 Sep:</strong> Valuation shifts from expensive to fair, with improved P/E and EV multiples</p>\n                    <p><strong>18 Sep:</strong> Stock recovers modestly to Rs.1,305.85, closing the week down 7.62%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,413.55</div></div>\n                    <div class=\"stat..."
      },
      {
        "title": "Fredun Pharmaceuticals Ltd Locks at Lower Circuit With 9.8% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/fredun-pharmaceuticals-ltd-hits-lower-circuit-amid-heavy-selling-pressure-4195014",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/FredunPharmaceu_stocks_hitting_lower_circuit_4195014.png",
        "date": "2026-09-16 10:00:47",
        "description": "At Rs 1,197.7, sellers were still queuing — but there were no buyers willing to take the other side. Fredun Pharmaceuticals Ltd locked at its lower circuit of 9.8% on 16 Jun 2026, with unfilled sell orders and a frozen price."
      },
      {
        "title": "Fredun Pharmaceuticals Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/fredun-pharmaceuticals-ltd-valuation-shifts-signal-renewed-price-attractiveness-4193964",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/FredunPharmaceu_valuationdot_4193964.png",
        "date": "2026-09-16 08:01:34",
        "description": "Fredun Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair price territory. This change, coupled with robust financial metrics and a strong market performance relative to benchmarks, positions the micro-cap pharmaceutical company as an increasingly attractive proposition for investors seeking quality exposure in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Fredun Pharmaceuticals Ltd is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/fredun-pharmaceuticals-ltd-is-rated-buy-4193143",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/FredunPharmaceu_mojoScore_4193143.png",
        "date": "2026-09-15 10:11:10",
        "description": "Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 August 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 15 September 2026, providing investors with the latest comprehensive analysis."
      },
      {
        "title": "Fredun Pharmaceuticals Ltd is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/fredun-pharmaceuticals-ltd-is-rated-buy-4182282",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/FredunPharmaceu_mojoScore_4182282.png",
        "date": "2026-09-04 10:11:07",
        "description": "Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 August 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 September 2026, providing investors with the latest insights into the company’s performance and outlook."
      }
    ],
    "total": 332,
    "sid": "1002605",
    "stock_news_url": "https://www.marketsmojo.com/news/fredun-pharmaceuticals-1002605"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "28-Sep-2026",
      "details": "Intimation of Trading Window Closure",
      "source": "BSE"
    },
    {
      "caption": "Revised Outcome Of Board Meeting Dated 16Th September 2026",
      "datetime": "22-Sep-2026",
      "details": "Revised Outcome of Board Meeting Dated 16th September 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "22-Sep-2026",
      "details": "Press Release by FPL dated- 22-09-2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Fredun Pharmaceuticals Ltd has declared <strong>7%</strong> dividend, ex-date: 23 Jun 26",
          "dt": "2026-06-23",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Fredun Pharmaceuticals Ltd has announced <strong>2:1</strong> bonus issue, ex-date: 16 Jul 26",
          "dt": "2026-07-16",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Fredun Pharmaceuticals Ltd is Rated Buy

2026-10-03 10:10:43

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 21 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 October 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Fredun Pharmaceuticals Gains 4.22%: Valuation Shift and Strong Fundamentals Drive the Week

2026-09-26 14:00:35

Key Events This Week

21 Sep: Rating downgraded to Buy amid expensive valuation

22 Sep: Valuation shift signals changing price attractiveness

24 Sep: Stock price dips amid broader market weakness

25 Sep: Week closes with modest gain at Rs.1,360.90

Week Open

Rs.1,305.85

Week Close

Rs.1,360.90

...

Read full news article

Fredun Pharmaceuticals Downgraded to Buy Amid Expensive Valuation Despite Strong Financials

2026-09-22 08:53:15

Fredun Pharmaceuticals Ltd has seen its investment rating downgraded from Strong Buy to Buy as of 21 Sep 2026, primarily due to a shift in valuation metrics despite continued robust financial performance and positive technical indicators. The micro-cap pharmaceutical company’s Mojo Score now stands at 77.0, reflecting a recalibrated outlook that balances impressive growth with stretched market multiples.

Read full news article

Fredun Pharmaceuticals Ltd: Valuation Shift Signals Changing Price Attractiveness

2026-09-22 08:01:13

Fredun Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

Fredun Pharmaceuticals Declines 7.62% Amid Valuation Shift and Circuit Breaker Event

2026-09-19 13:02:25

Key Events This Week

15 Sep: Stock opens at Rs.1,325.05, down 6.26% amid broad market weakness

16 Sep: Fredun hits lower circuit at Rs.1,197.70, down 9.8%, amid panic selling

16 Sep: Valuation shifts from expensive to fair, with improved P/E and EV multiples

18 Sep: Stock recovers modestly to Rs.1,305.85, closing the week down 7.62%

Week Open

Rs.1,413.55

Read full news article

Fredun Pharmaceuticals Ltd Locks at Lower Circuit With 9.8% Loss — Sellers Queue, No Buyers in Sight

2026-09-16 10:00:47

At Rs 1,197.7, sellers were still queuing — but there were no buyers willing to take the other side. Fredun Pharmaceuticals Ltd locked at its lower circuit of 9.8% on 16 Jun 2026, with unfilled sell orders and a frozen price.

Read full news article

Fredun Pharmaceuticals Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-09-16 08:01:34

Fredun Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair price territory. This change, coupled with robust financial metrics and a strong market performance relative to benchmarks, positions the micro-cap pharmaceutical company as an increasingly attractive proposition for investors seeking quality exposure in the Pharmaceuticals & Biotechnology sector.

Read full news article

Fredun Pharmaceuticals Ltd is Rated Buy

2026-09-15 10:11:10

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 August 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 15 September 2026, providing investors with the latest comprehensive analysis.

Read full news article

Fredun Pharmaceuticals Ltd is Rated Buy

2026-09-04 10:11:07

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 August 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

View All News